<div id="readability-page-1"><p>Heck Capital Advisors LLC purchased a new position in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  purchased 7,661 shares of the company's stock, valued at approximately $1,108,000.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li></ul><p>Other hedge funds and other institutional investors have also modified their holdings of the company. IFS Advisors LLC increased its position in shares of  Johnson &amp; Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the period.  Highline Wealth Partners LLC acquired a new position in  Johnson &amp; Johnson during the 3rd quarter worth $31,000.  RPg Family Wealth Advisory LLC purchased a new stake in  Johnson &amp; Johnson during the 3rd quarter worth about $35,000.  Mowery &amp; Schoenfeld Wealth Management LLC raised its position in  Johnson &amp; Johnson by 58.7% in the 3rd quarter. Mowery &amp; Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after purchasing an additional 91 shares in the last quarter.  Finally, Activest Wealth Management acquired a new position in shares of  Johnson &amp; Johnson during the third quarter worth about $40,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analyst Ratings Changes</h2><p>A number of equities analysts recently commented on the stock. Stifel Nicolaus lowered their target price on shares of Johnson &amp; Johnson from $170.00 to $155.00 and set a &#34;hold&#34; rating for the company in a research note on Thursday, January 23rd. Barclays upped their price target on Johnson &amp; Johnson from $159.00 to $166.00 and gave the company an &#34;equal weight&#34; rating in a report on Tuesday, January 28th. Raymond James cut their price objective on shares of Johnson &amp; Johnson from $170.00 to $165.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday, January 23rd. Morgan Stanley lowered their target price on shares of Johnson &amp; Johnson from $175.00 to $163.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, January 23rd. Finally, Wells Fargo &amp; Company decreased their price objective on shares of Johnson &amp; Johnson from $166.00 to $152.00 and set an &#34;equal weight&#34; rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $170.67.</p><ul><li>3 Stocks Upgraded by Bank of America – Here's Why They're Bullish</li></ul><p><b>View Our Latest Stock Report on JNJ</b></p><h2>Johnson &amp; Johnson Price Performance</h2><p>Shares of NYSE JNJ opened at $151.82 on Tuesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson &amp; Johnson has a one year low of $140.68 and a one year high of $168.85. The company's fifty day moving average is $147.61 and its two-hundred day moving average is $156.12. The firm has a market capitalization of $365.53 billion, a P/E ratio of 22.83, a PEG ratio of 2.44 and a beta of 0.52. </p><ul><li>Why Traders Are Buying the Dip on Johnson &amp; Johnson Stock</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson &amp; Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.29 EPS.  Analysts forecast that  Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.27%. Johnson &amp; Johnson's dividend payout ratio  is presently 74.59%. </p><h2>Insider Activity at Johnson &amp; Johnson</h2><p>In other Johnson &amp; Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson &amp; Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders. </p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Read More</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Consumer Discretionary Stocks Explained</li><li>How to Invest in Small Cap Stocks</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>These Are the Dividend Stocks Insiders Bought in January</li><li>What is a support level?</li><li>How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Heck Capital Advisors LLC invested $1.11 million in Johnson & Johnson (NYSE: JNJ) by acquiring 7,661 shares during the fourth quarter, as reported in their 13F filing with the SEC. Other institutional investors also adjusted their holdings, with IFS Advisors LLC increasing their position by 138.9%. Analysts have mixed ratings on the stock, with an average target price of $170.67. Johnson & Johnson reported a quarterly EPS of $2.04, exceeding estimates, and announced a quarterly dividend of $1.24, yielding 3.27%.</p>

Heck Capital Advisors LLC Invests $1.11 Million in Johnson & Johnson (NYSE:JNJ)